• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

儿童药物反应伴嗜酸性粒细胞增多和全身症状(DReSS)的管理和长期结局:范围综述。

Management and Long-Term Outcomes of Drug Reaction with Eosinophilia and Systemic Symptoms (DReSS) in Children: A Scoping Review.

机构信息

Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.

Division of Clinical Pharmacology and Toxicology, Department of Paediatrics, The Hospital for Sick Children, 555 University Ave, Toronto, ON, M5G 1X8, Canada.

出版信息

Am J Clin Dermatol. 2024 Jul;25(4):609-621. doi: 10.1007/s40257-024-00867-y. Epub 2024 May 16.

DOI:10.1007/s40257-024-00867-y
PMID:38755503
Abstract

Drug reaction with eosinophilia and systemic symptoms (DReSS) is known to cause mortality and long-term sequelae in the pediatric population, however there are no established clinical practice guidelines for the management of pediatric DReSS. We conducted a scoping review, according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, to summarize the currently available data on treatment, mortality, and long-term sequelae of DReSS in children (aged 0-18 years). Data from 644 individuals revealed that various treatment strategies are being used in the management of pediatric DReSS, and strategies were often used in combination. The diversity in treatment approaches cannot be solely attributed to age or disease severity and reflects the lack of evidence-based management guidelines for DReSS. Children are also at risk of developing autoimmune sequelae following DReSS, most commonly thyroid disease and type 1 diabetes mellitus. We found that the eventual development of autoimmune disease was more often associated with DReSS caused by antibiotics, especially minocycline and sulfamethoxazole, in comparison with individuals who did not develop sequelae. In this study, we identify strengths and weaknesses in the currently available literature and highlight that future prospective studies with structured and long-term follow-up of children with DReSS are needed to better understand potential risk factors for mortality and development of sequelae after DReSS.

摘要

药物反应伴嗜酸性粒细胞增多和全身性症状(DReSS)已知可导致儿科人群死亡和长期后遗症,但目前尚无针对儿科 DReSS 管理的既定临床实践指南。我们根据系统评价和荟萃分析的首选报告项目(PRISMA)指南进行了范围综述,以总结目前关于儿童(0-18 岁)DReSS 的治疗、死亡率和长期后遗症的数据。来自 644 个人的数据表明,正在使用各种治疗策略来管理儿科 DReSS,并且这些策略经常联合使用。治疗方法的多样性不能仅仅归因于年龄或疾病严重程度,这反映了缺乏针对 DReSS 的循证管理指南。儿童在 DReSS 后也有发生自身免疫后遗症的风险,最常见的是甲状腺疾病和 1 型糖尿病。我们发现,与没有发生后遗症的个体相比,抗生素引起的 DReSS,尤其是米诺环素和磺胺甲噁唑,更常导致自身免疫疾病的最终发展。在这项研究中,我们确定了现有文献的优缺点,并强调需要未来进行前瞻性研究,对 DReSS 患儿进行结构化和长期随访,以更好地了解 DReSS 后死亡率和后遗症发展的潜在风险因素。

相似文献

1
Management and Long-Term Outcomes of Drug Reaction with Eosinophilia and Systemic Symptoms (DReSS) in Children: A Scoping Review.儿童药物反应伴嗜酸性粒细胞增多和全身症状(DReSS)的管理和长期结局:范围综述。
Am J Clin Dermatol. 2024 Jul;25(4):609-621. doi: 10.1007/s40257-024-00867-y. Epub 2024 May 16.
2
Drug reaction with eosinophilia and systemic symptoms: Pediatric case series and literature review.药物性嗜酸性粒细胞增多及系统症状:儿科病例系列与文献综述
Pediatr Dermatol. 2019 Nov;36(6):887-892. doi: 10.1111/pde.13949. Epub 2019 Aug 18.
3
Clinical Presentation and Diagnosis of Drug Reaction with Eosinophilia and Systemic Symptoms (DReSS) in Children: A Scoping Review.儿童嗜酸性粒细胞增多和全身症状药物反应(DReSS)的临床表现与诊断:一项范围综述
Clin Rev Allergy Immunol. 2024 Feb;66(1):112-123. doi: 10.1007/s12016-024-08983-7. Epub 2024 Mar 11.
4
Drug-specific presentation and outcome of drug reaction with eosinophilia and systemic symptoms (DRESS) in children: a scoping review.儿童药物性嗜酸性粒细胞增多和系统症状(DRESS)的药物特异性表现及结局:一项范围综述
Clin Exp Dermatol. 2025 Jan 27;50(2):408-411. doi: 10.1093/ced/llae418.
5
Pediatric drug reaction with eosinophilia and systemic symptoms: A systematic review of the literature.儿童嗜酸性粒细胞增多和全身症状的药物反应:文献系统评价
Pediatr Dermatol. 2020 Jan;37(1):124-129. doi: 10.1111/pde.14044. Epub 2019 Nov 5.
6
Sequelae in 145 patients with drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms: survey conducted by the Asian Research Committee on Severe Cutaneous Adverse Reactions (ASCAR).145例药物性超敏反应综合征/伴嗜酸性粒细胞增多和全身症状的药物反应患者的后遗症:由亚洲严重皮肤不良反应研究委员会(ASCAR)开展的调查
J Dermatol. 2015 Mar;42(3):276-82. doi: 10.1111/1346-8138.12770. Epub 2015 Jan 27.
7
DRESS (drug reaction with eosinophilia and systemic symptoms): a possible prolonged course with sequelae.药物超敏反应伴嗜酸性粒细胞增多和全身症状(DRESS):病程可能迁延并伴有后遗症。
Eur J Dermatol. 2024 Dec 1;34(6):587-594. doi: 10.1684/ejd.2024.4801.
8
Late sequelae of drug reaction with eosinophilia and systemic symptoms (DRESS) cause thyroid dysfunction and thyroiditis: review of literature.药物反应伴嗜酸性粒细胞增多和全身症状(DRESS)的迟发后遗症可导致甲状腺功能障碍和甲状腺炎:文献复习。
J Pediatr Endocrinol Metab. 2022 Feb 4;35(5):567-575. doi: 10.1515/jpem-2021-0685. Print 2022 May 25.
9
Drug reaction with eosinophilia and systemic symptoms in a cohort of Asian children.一组亚洲儿童中的药物反应伴嗜酸性粒细胞增多和全身症状
Pediatr Dermatol. 2019 May;36(3):324-329. doi: 10.1111/pde.13812. Epub 2019 Mar 28.
10
Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Syndrome in Children: A Case Report.儿童药物超敏反应伴嗜酸性粒细胞增多和全身症状(DRESS)综合征:一例报告
J Investig Allergol Clin Immunol. 2017;27(2):144-146. doi: 10.18176/jiaci.0140.

引用本文的文献

1
Clinical diagnosis and management of drug reaction with eosinophilia and systemic symptoms (DRESS) in children: An EAACI position paper.儿童药物超敏反应伴嗜酸性粒细胞增多和全身症状(DRESS)的临床诊断与管理:欧洲变态反应和临床免疫学会立场文件
Pediatr Allergy Immunol. 2025 Jul;36(7):e70103. doi: 10.1111/pai.70103.

本文引用的文献

1
Clinical Presentation and Diagnosis of Drug Reaction with Eosinophilia and Systemic Symptoms (DReSS) in Children: A Scoping Review.儿童嗜酸性粒细胞增多和全身症状药物反应(DReSS)的临床表现与诊断:一项范围综述
Clin Rev Allergy Immunol. 2024 Feb;66(1):112-123. doi: 10.1007/s12016-024-08983-7. Epub 2024 Mar 11.
2
Drug Reaction With Eosinophilia and Systemic Symptoms: A Systematic Review.药物相关性嗜酸性粒细胞增多和全身症状:系统评价。
J Allergy Clin Immunol Pract. 2023 Jun;11(6):1856-1868. doi: 10.1016/j.jaip.2023.02.035. Epub 2023 Mar 7.
3
Drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms following nivolumab and ipilimumab in a pediatric patient with melanoma.
纳武利尤单抗和伊匹单抗治疗黑色素瘤儿童患者后引起的药物诱导超敏反应综合征/药物伴嗜酸性粒细胞增多和全身症状。
Pediatr Dermatol. 2022 May;39(3):486-487. doi: 10.1111/pde.14940.
4
Graves' disease: an uncommon cause of late sequelae following DRESS (drug reaction with eosinophilia and systemic symptoms).格雷夫斯病:药物超敏反应伴嗜酸性粒细胞增多和全身症状(DRESS)后迟发性后遗症的罕见病因。
Clin Exp Pediatr. 2022 Dec;65(12):602-604. doi: 10.3345/cep.2022.00381. Epub 2022 Jun 22.
5
T-cell-mediated hypersensitivity to lumacaftor and ivacaftor in cystic fibrosis.囊性纤维化中T细胞介导的对鲁马卡托和依伐卡托的超敏反应。
Pediatr Allergy Immunol. 2022 Jun;33(6):e13815. doi: 10.1111/pai.13815.
6
Late sequelae of drug reaction with eosinophilia and systemic symptoms (DRESS) cause thyroid dysfunction and thyroiditis: review of literature.药物反应伴嗜酸性粒细胞增多和全身症状(DRESS)的迟发后遗症可导致甲状腺功能障碍和甲状腺炎:文献复习。
J Pediatr Endocrinol Metab. 2022 Feb 4;35(5):567-575. doi: 10.1515/jpem-2021-0685. Print 2022 May 25.
7
Updates and Insights in the Diagnosis and Management of DRESS Syndrome.药物超敏反应综合征诊断与管理的最新进展与见解
Curr Dermatol Rep. 2021;10(4):192-204. doi: 10.1007/s13671-021-00348-z. Epub 2021 Nov 9.
8
Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): Series of 49 French Pediatric Cases.药物反应伴嗜酸性粒细胞增多和全身症状(DRESS):49 例法国儿科病例系列。
J Allergy Clin Immunol Pract. 2022 Jan;10(1):267-274.e5. doi: 10.1016/j.jaip.2021.07.025. Epub 2021 Jul 29.
9
Pediatric drug reaction with eosinophilia and systemic symptoms: A systematic review of the literature, with a focus on relapsing cases.儿童嗜酸性粒细胞增多和全身症状的药物反应:文献系统综述,重点关注复发病例。
Pediatr Dermatol. 2021 Jan;38(1):125-131. doi: 10.1111/pde.14446. Epub 2020 Nov 6.
10
Alopecia universalis after drug reaction with eosinophilia and systemic symptoms (Dress).药物相关性嗜酸性粒细胞增多和全身症状(DRESS)反应后出现普秃。
Pediatr Dermatol. 2020 Sep;37(5):947-949. doi: 10.1111/pde.14217. Epub 2020 Jun 11.